Serious adverse events 22 weeks · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in serious adverse events 22 weeks compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
Hospital admission (exacerbation) · adults with asthma not well controlled on ICS
It is very uncertain whether long‐acting muscarinic antagonists (LAMA) add‐on changes exacerbations (hospital) compared with long‐acting beta2‐agonists (LABA) add‐on (very low certainty).
1 finding from 1 review
FEV1 · adults with asthma not well controlled on ICS
1 finding from 1 review
ACQ score Scale = 0 to 6 (0 = no impairment; 6 = maximum impairment) · adults with asthma not well controlled on ICS
1 finding from 1 review
Adverse events (all) · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in adverse events (all) compared with long‐acting beta2‐agonists (LABA) add‐on (moderate certainty).
1 finding from 1 review
Treatment failure Need to intensify therapy/ED or hospital admission · exacerbations of COPD
Systemic corticosteroid leads to lower treatment failure Need to intensify therapy/ED or hospital admission compared with placebo (high certainty).
1 finding from 1 review
Mortality after discharge (1‐3 months) · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in mortality after discharge (1‐3 months) compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Length of hospitalisation (days) · exacerbations of COPD
1 finding from 1 review
Adverse drug effect—hyperglycaemia · exacerbations of COPD
Treatment route: intravenous corticosteroid probably leads to higher adverse drug effect ‐ hyperglycaemia compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Arterial blood gas tension: PaO2 after 3 months mmHg · exacerbations of COPD
1 finding from 1 review
Relapse Treatment for AE of COPD or hospital re‐admission · exacerbations of COPD
Systemic corticosteroid showed no clear difference in relapse Treatment for AE of COPD or hospital re‐admission compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 · exacerbations of COPD
1 finding from 1 review
Breathlessness ‐ early effect VAS 0‐10. Scale from: 0 to 10. · exacerbations of COPD
1 finding from 1 review
Adverse drug reactions · exacerbations of COPD
Systemic corticosteroid leads to higher adverse drug effect compared with placebo (high certainty).
1 finding from 1 review
Hyperglycaemia · exacerbations of COPD
Systemic corticosteroid leads to higher hyperglycaemia compared with placebo (high certainty).
1 finding from 1 review
Treatment failure Need for additional treatment · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in treatment failure Need to intensify therapy compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Relapse Hospital readmission for COPD · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in relapse Hospital readmission for COPD compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Breathlessness ‐ early effect VAS 0‐10. Scale from: 0 to 10. · exacerbations of COPD
1 finding from 1 review
Change from baseline in morning PEFR (L/min) Duration of trials: 8 to 13 weeks · patients with chronic asthma
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · patients with chronic asthma
1 finding from 1 review